Axonics, Inc. (AXNX)

Market Cap	3.63B
Revenue (ttm)	431.90M
Net Income (ttm)	-5.66M
Shares Out	51.11M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	165.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	70.98
Day's Range	70.98 - 70.98
52-Week Range	55.09 - 71.05
Beta	0.83
Analysts	Hold
Price Target	71.00 (+0.03%)
Earnings Date	Nov 7, 2024

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to r...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 797
• Stock Exchange: NASDAQ
• Ticker Symbol: AXNX
• Website: https://www.axonics.com

Financial Performance

In 2023, Axonics's revenue was $366.38 million, an increase of 33.86% compared to the previous year's $273.70 million. Losses were -$6.09 million, -89.80% less than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for AXNX stock is "Hold." The 12-month stock price forecast is $71.0, which is an increase of 0.03% from the latest price.

Price Target

$71.0

(0.03% upside)

Analyst Consensus: Hold